Abstract
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder caused by TPP1 deficiency. Intracerebroventricular cerliponase alfa slows motor-language decline, although outcomes vary with disease stage at treatment initiation. Intrafamilial comparisons remain scarce, particularly in Latin America. We report two Colombian siblings carrying identical compound heterozygous TPP1 variants (c.622C>T [p.Arg208*] and c.887-10A>G) with markedly reduced enzyme activity. The older brother began enzyme replacement therapy (ERT) at age 11 with advanced neurologic impairment; whereas his sister started presymptomatically at age 3 following cascade testing. Clinical scales, neuroimaging, and cerebrospinal fluid neurofilament light (CSF NfL) levels were analyzed during 5-6 years of treatment. Before diagnosis, the brother developed language regression, ataxia, epilepsy, and visual decline. After ERT initiation, no further major motor milestone loss ocurred, seizures remained controlled, and severe disability persisted; CSF NfL decreased from 1,334 to 504 pg/mL during maintenance. His sister remained neurologically intact at age 9, with preserved motor-language function, normal MRI, and maintenance-phase CSF NfL levels of 359-531 pg/mL. These divergent intrafamilial trajectories support early TPP1 testing and prompt cascade screening in at-risk siblings, although longer follow-up is required to establish the durability of presymptomatic benefit.

This publication has 25 references indexed in Scilit: